Mark T Nelson Selected Research

Inwardly Rectifying Potassium Channels (Inward Rectifier Potassium Channels)

1/2021	Impaired capillary-to-arteriolar electrical signaling after traumatic brain injury.
1/2021	PIP2 corrects cerebral blood flow deficits in small vessel disease by rescuing capillary Kir2.1 activity.
1/2021	Traumatic Brain Injury Impairs Systemic Vascular Function Through Disruption of Inward-Rectifier Potassium Channels.
1/2021	Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark T Nelson Research Topics

Disease

7	Hyperemia 01/2021 - 04/2009
6	Hypertension (High Blood Pressure) 01/2021 - 09/2003
5	CADASIL 01/2022 - 02/2015
4	Cystitis 01/2021 - 04/2006
4	Inflammation (Inflammations) 01/2021 - 04/2006
3	Wounds and Injuries (Trauma) 01/2021 - 01/2019
3	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2021 - 12/2014
3	Overactive Urinary Bladder (Overactive Bladder) 10/2008 - 08/2004
3	Urinary Incontinence 10/2008 - 01/2003
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 10/2013
2	Ischemia 01/2022 - 10/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2008
2	Erectile Dysfunction 07/2008 - 09/2005
1	Amyloid Plaque 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Herpes Zoster 01/2021
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2021
1	Cerebral Small Vessel Diseases 01/2021
1	Cognitive Dysfunction 01/2021
1	Hyperplasia 01/2020
1	Urinary Retention 01/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Epilepsy (Aura) 01/2019
1	Vascular Diseases (Vascular Disease) 01/2019
1	Underactive Urinary Bladder 12/2018
1	Neoplasms (Cancer) 11/2018
1	Starvation 01/2017
1	Osteonecrosis (Kienbock's Disease) 10/2016
1	Bone Diseases (Bone Disease) 10/2016
1	Sepsis (Septicemia) 09/2016
1	Thrombosis (Thrombus) 01/2016
1	Channelopathies 02/2015
1	Acidosis 01/2012
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2011
1	Whooping Cough (Pertussis) 11/2010
1	Encephalomyelitis (Myeloencephalitis) 11/2010

Drug/Important Bio-Agent (IBA)

8	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 01/2012 - 09/2003
6	PotassiumIBA 01/2022 - 09/2005
4	Inwardly Rectifying Potassium Channels (Inward Rectifier Potassium Channels)IBA 01/2021 - 01/2021
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 04/2006
3	Vasodilator Agents (Vasodilators)IBA 03/2016 - 01/2012
2	Potassium Channels (Potassium Channel)IBA 01/2022 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2016
2	Kir2.1 channelIBA 01/2021 - 01/2021
2	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 07/2019 - 04/2006
2	CalciumIBA 10/2016 - 09/2005
2	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2016 - 02/2015
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2014 - 07/2008
2	Cyclic GMP-Dependent Protein Kinase Type IIBA 07/2008 - 05/2008
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	Mineralocorticoid Receptor AntagonistsIBA 01/2021
1	claudin 8IBA 01/2021
1	TRPA1 Cation ChannelIBA 01/2021
1	Eplerenone (Inspra)FDA LinkGeneric 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	MineralocorticoidsIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2021
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021
1	ZincIBA 01/2021
1	Calcium Channels (Calcium Channel)IBA 01/2021
1	Amlodipine (Norvasc)FDA LinkGeneric 01/2021
1	AnkyrinsIBA 01/2021
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2021
1	Losartan (Cozaar)FDA LinkGeneric 01/2021
1	Angiotensin II Type 1 Receptor BlockersIBA 01/2021
1	Phospholipases A2 (Phospholipase A2)IBA 01/2021
1	Claudin-1IBA 01/2021
1	FibrinIBA 01/2020
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2020
1	Contractile ProteinsIBA 01/2020
1	Histones (Histone)IBA 01/2019
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2019
1	ezogabine (retigabine)IBA 01/2019
1	CollagenIBA 12/2018
1	Arginine (L-Arginine)FDA Link 01/2017
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	CytokinesIBA 09/2016
1	LipopolysaccharidesIBA 09/2016
1	InterleukinsIBA 09/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2016
1	Interleukin-6 (Interleukin 6)IBA 09/2016
1	VitronectinIBA 03/2016
1	Extracellular Matrix ProteinsIBA 03/2016
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2016
1	Tissue Inhibitor of Metalloproteinase-3IBA 01/2016
1	Notch3 ReceptorIBA 02/2015
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2014
1	Nerve Growth Factor (NGF)IBA 10/2014
1	Angiotensin IIIBA 07/2014
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 07/2014
1	salicylhydroxamic acid (SHAM)IBA 10/2013
1	Histamine H1 Receptors (Histamine H1 Receptor)IBA 11/2010

Therapy/Procedure

4	Therapeutics 11/2018 - 01/2003
1	Lasers (Laser) 01/2022
1	Punctures 09/2016
1	Ligation 09/2016
1	Heart-Assist Devices 01/2016